Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 2/20 | 0.56 |
| ▸ | KIT | P10721 | 1/20 | 0.56 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.56 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.38 |
| ▸ | F10 | P00742 | 2/20 | 0.33 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | F2 | P00734 | 2/20 | 0.32 |
| ▸ | PLG | P00747 | 2/20 | 0.32 |
| ▸ | PLAU | P00749 | 2/20 | 0.32 |
| ▸ | PLAT | P00750 | 2/20 | 0.32 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.32 |
| ▸ | KLK1 | P06870 | 1/20 | 0.32 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.32 |
| ▸ | UBE2T | Q9NPD8 | 2/20 | 0.30 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21153067 | 0.86 | FLT3 (0.56) | FLT3KITNTRK3ST14F10 | |
| SCHEMBL17469648 | 0.86 | KIT (0.75) | FLT3KITNTRK3ST14F10 | |
| SCHEMBL17469789 | 0.83 | KIT (0.52) | FLT3KITNTRK3ST14TDP1 | |
| SCHEMBL21152352 | 0.79 | KIT (0.49) | FLT3KITNTRK3ST14 | |
| SCHEMBL21153071 | 0.77 | KIT (0.56) | FLT3KITNTRK3ST14CTDSP1 | |
| SCHEMBL17469650 | 0.72 | FLT3 (0.75) | FLT3KITNTRK3ST14F10 | |
| SCHEMBL17469652 | 0.72 | KIT (0.75) | FLT3KITNTRK3ST14TDP1 | |
| SCHEMBL17469649 | 0.72 | KIT (1.00) | FLT3KITNTRK3ST14TDP1 | |
| SCHEMBL21152053 | 0.71 | KIT (0.44) | FLT3KITNTRK3TDP1PLAU | |
| SCHEMBL17469651 | 0.70 | FLT3 (0.71) | FLT3KITNTRK3ST14TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190209548-A1 | LINKED DIARYL COMPOUNDS WITH ANTICANCER PROPERTIES AND METHODS OF USING THE SAME | UNIVERSITY OF MARYLAND, BALTIMORE | 2019-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190209548-A1 | LINKED DIARYL COMPOUNDS WITH ANTICANCER PROPERTIES AND METHODS OF USING THE SAME | MCL1, DPYD, TOP2B | FLT3 2354/4885KIT 2616/4885NTRK3 4453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.